Aardvark Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $81.70M
- P/E (TTM)
- –
- Dividend yield
- –
About Aardvark Therapeutics
Pharmaceutical Preparations, SIC 2834
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics to activate innate homeostatic pathways for treating metabolic conditions. The company primarily targets bitter taste receptors expressed in the gut lumen to stimulate the release of endogenous signaling molecules that help alleviate hunger. Its product candidates include ARD-101, an oral gut-restricted agonist under evaluation for hyperphagia associated with Prader-Willi Syndrome, and ARD-201, a combination therapy intended for obesity and weight regain prevention.
The company operates in the United States and has conducted clinical trial activities across several international jurisdictions, including Australia, the United Kingdom, South Korea, and Canada. Aardvark Therapeutics maintains its principal executive offices in San Diego, California. The company relies on third parties and clinical sites to support the ongoing development and evaluation of its investigational product candidates across these geographic regions.
Summary of the business section of Aardvark Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aardvark Therapeutics, Inc.
- Founded
- 2017
- Headquarters
- San Diego, CA
- Address
- 4370 La Jolla Village Drive, Suite 1050 92122
- Phone
- (858) 225-7696
- Website
- aardvarktherapeutics.com
- Employees
- 40, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C, San Diego, California
Stock & identifiers
- Ticker
- AARD
- Exchange
- Nasdaq
- IPO date
- Feb 13, 2025
- Shares outstanding
- 22M, Jul 31, 2026
- Public float
- $162.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1774857
- CUSIP
- 002942100
- ISIN
- US0029421007
- EIN
- 82-1606367
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tien-Li Lee | Chief Executive Officer, Director | 3,025,641 |
| Nelson Sun | See Remarks | 35,475 |
| Manasi Jaiman | Chief Medical Officer | – |
| Bryan Jones | Chief Operating Officer | 1,250 |
| Jeffrey Chi | Director | 133,364 |
| Susan E. Graf | Director | – |
| Roy D. Baynes | Director | – |
| Victor Edward Tong Jr | Director | – |
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 40 employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 13, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 10, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |